Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis.

By D. Denning, P. Ribaud, N. Milpied, D. Caillot, R. Herbrecht, E. Thiel, A. Haas, M. Ruhnke, H. Lode. Clinical Infectious Diseases, 2002

871 citations recorded by the source corpus.

Subfields: Epidemiology, Infectious Diseases, Ophthalmology

View Paper: https://www.semanticscholar.org/paper/6cc63ffe1c6f010c131074407b9097ff25977506

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

In Infectious Diseases

Citations in the corpus

Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. (2016, background): “Toxicity is more common with higher drug levels but is not predictable based solely on this criterion [216, 220, 227].”
Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. (2008, background): “Voriconazole and itraconazole have been used successfully in the treatment of this form of pulmonary aspergillosis [116].”
Resistance to Antifungal Agents: Mechanisms and Clinical Impact (2008, background): “As for azole compounds, the increasing use of serum drug levels has begun to emphasize the correlation between direct drug exposure and outcome [111–114].”
Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America. (2008, background): “Therapeutic drug monitoring, although not standard of care, may be considered in some patients receiving treatment with voriconazole, because drug toxicity has been observed when patients have higher serum concentrations and reduced clinical response has been observed when patients have lower concen”
Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. (2018, background): “Voriconazole A II [333,716,624,717] L-AmB 3e5 mg/kg B II Majority voted for BII others for AII [676,718,719] ABLC 5 mg/kg C II [570,719,720,628] ABCD No longer commercially available [721,722]”
Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. (2007, methodology): “Nevertheless, the overall successful response rate in this study is similar to that of other salvage studies of therapies for invasive aspergillosis, including amphotericin B lipid complex (42%) [8], caspofungin (45%) [7], and voriconazole (38%) [23].”
Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. (2008, background): “Variability in oral bioavailability associated with meals and hepatic first-pass effect might have contributed to lower exposure [1, 13, 27].”
Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. (2014, background): “79 Subsequently, a number of retrospective studies from single centres also suggested a relationship between drug exposure and clinical outcome.”
Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. (2004, neutral): “studies of salvage therapy with voriconazole [18, 19, 36].”
Aspergillus Infections in Transplant Recipients (2005, result): “In a number of small analyses of the use of voriconazole in transplant recipients, the outcome has been similar to that observed in the randomized trial described above (19, 72, 173, 194).”
Voriconazole treatment for less-common, emerging, or refractory fungal infections. (2003, background): “In refractory aspergillosis, the overall success rate for ABLC was 42% (55 of 130 patients), compared with a rate of 44% (62 of 142) for voriconazole in this study, and compared with a previous report of voriconazole salvage therapy for aspergillosis, which reported success in 21 (38%) of 56 patient”